A site director at a community cancer center gets the call in late August: a top-tier sponsor wants to activate her site on a new oncology protocol, the timeline is aggressive, and the network contract is already in place. She should be relieved. Instead, she pulls up her startup tracker and starts counting: IRB submission, budget reconciliation against the master agreement, pharmacy qualification, lab certification, coordinator training, system access for EDC and IRT. The network deal did not make those steps disappear. It just moved the negotiation upstream — and left the execution squarely on her.
That is the operational reality sitting underneath the August 13 announcement that Sarah Cannon Research Institute and Merck are collaborating to expand patient access to oncology clinical trials at community-based sites across the U.S. The collaboration deploys SCRI’s Accelero™ delivery model across a network that, according to SCRI’s own announcement, includes over 200 locations in more than 20 states and approximately 1,500 oncology physicians. That footprint is real, and the enrollment math behind targeting it is sound. But a site count is a potential, not a throughput. The gap between those two numbers is where trials actually live and die.
Why Community Sites Are the Right Bet — and the Hard One
The case for community-based oncology enrollment is not complicated. A study published in the Journal of Clinical Oncology covering the 2013 to 2017 period estimated overall cancer treatment trial participation at 7.1% nationally, with NCI-designated comprehensive cancer centers carrying dramatically higher rates than community programs. Most patients, of course, receive their oncology care at community sites. The enrollment gap is structural: the patients are there, the trials are not, or when they are, the operational infrastructure to run them rarely keeps pace with the science.
Community sites are not smaller academic centers. They are different organisms. A coordinator at a comprehensive cancer center may carry three to five concurrent oncology protocols with dedicated research pharmacy support, a full-time regulatory affairs coordinator, and an in-house IRB with predictable turnaround. A community site coordinator is often running the same three to five protocols with half the support staff, a contracted central IRB relationship she did not negotiate, a pharmacy arrangement that depends on one pharmacist’s schedule, and a site management organization that may or may not have read the latest protocol amendment before forwarding it to the PI. The operational density per staff member is fundamentally different, and no master collaboration agreement changes that arithmetic on day one of activation.
The Merck-SCRI structure is designed to address exactly this gap by standardizing what can be standardized upstream. Federated network agreements, pre-negotiated budget templates, centralized IRB pathways, and unified eClinical infrastructure can genuinely compress the startup timeline when they function as designed. The question every site director in that 200-location network should be asking is: which of those pieces are actually in place for my site, and which ones exist only at the network level?
That distinction matters because of where startup delays actually originate. Across oncology networks, the compressible time is not usually in IRB review once a submission is complete — it is in the weeks before submission: protocol feasibility reconciliation, budget gap identification, site-specific pharmacy SOPs, and coordinator training documentation. A master agreement accelerates contracting. It does not automatically accelerate the site’s internal readiness assessment, and sponsors who conflate the two end up with a signed agreement and a site that cannot receive its first patient for another 60 days.
The Activation Math Nobody Talks About
Here is the operational question the Accelero™ model has to answer: what is the realistic site activation rate across 200-plus locations, and what does the long tail look like?
In any large oncology network activation, the distribution is rarely uniform. A subset of sites, typically those with experienced coordinators, established sponsor relationships, and mature SOPs, activate quickly and carry disproportionate early enrollment. The remaining sites activate on a delayed curve driven by staff capacity, local pharmacy constraints, competing protocol commitments, and protocol-specific complexity. For a Merck oncology program, which may involve combination immunotherapy regimens with detailed safety monitoring requirements, a site that has never run a PD-1 inhibitor trial will need more than a network contract to be operationally ready — it needs hands-on SIV preparation, a confirmed pharmacy handling procedure, and a coordinator who has actually walked through the safety reporting timelines under ICH E6(R3) Section 5.17.
Sites I work with across community oncology networks consistently flag the same pressure point: the sponsor-side assumption that a pre-qualified network site is a ready site. Qualification and readiness are different documents. Qualification confirms the site has the patient population, the PI credentials, and the infrastructure in principle. Readiness confirms the coordinator is trained on the protocol, the IRT account is active, the lab kits are on the shelf, and the first subject’s eConsent is loaded and tested. Conflating those two stages is how you get to a site activation meeting where the site is technically “open” and practically nowhere near enrolling.
The FDA’s final guidance on decentralized clinical trial elements, which applies directly to the community-site model SCRI and Merck are scaling, is explicit that sponsors bear responsibility for ensuring site capabilities match the protocol’s operational requirements — not just the clinical ones. That responsibility does not transfer to a network agreement. It transfers to a monitoring plan, a site readiness checklist, and a pre-activation call that asks the hard questions before first-patient-in pressure begins.
What Operators Need to Do Before the First SIV
For site directors inside the SCRI network receiving Merck protocol activations under this collaboration: do not wait for the CRA to surface your readiness gaps at the SIV. Run your own gap assessment the week the protocol lands. Pull the pharmacy section and map it against your current IP handling SOP. Check whether your central IRB relationship under the network agreement covers the specific amendment cycle for this protocol type, or whether you have local committee obligations that the master agreement does not absorb. Confirm that your coordinator’s oncology GCP training is current under the ICH E6(R3) standard Merck will expect — not the version she completed three years ago for a different sponsor’s requirement.
For Merck’s clinical operations team and SCRI’s network management: the Accelero™ model will be judged by first-patient-in timelines at sites that have never run a Merck oncology program before, not at the flagship SCRI centers that already have the infrastructure. The 7.1% national enrollment rate cited in the JCO data did not persist because sponsors lacked ambition. It persisted because activation complexity at community sites was consistently underestimated. The collaboration’s real measure is whether it builds site-specific readiness support into the activation process — not whether it produces a signed master agreement in record time.
Watch for whether SCRI publishes site activation timelines and first-patient-in metrics from the Merck collaboration in the next 12 to 18 months. That data will tell you whether Accelero™ compresses the startup curve at the tail of the network or only at its center.
References
- FierceBiotech — “Merck and Sarah Cannon team up to boost oncology trial efficiency”
- BusinessWire — “Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials”
- Journal of Clinical Oncology — “National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data”
- FDA — Guidance on Conducting Clinical Trials With Decentralized Elements
